๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Colorectal Cancer (MSI-H)

Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer NCT07352280n/a1 site๐Ÿ“ Beijing Cancer Institute and Hospital, Chinese Academy of Medical Sโ€ฆ Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors NCT06974110Phase 115 sites๐Ÿ“ Phoenix๐Ÿ“ San Diego๐Ÿ“ Tampa MOMA Therapeutics ยท Tests: MOMA-341, Irinotecan, Immunotherapy DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition NCT05770102Phase 2, Phase 327 sites๐Ÿ“ Belfast๐Ÿ“ Birmingham๐Ÿ“ Birmingham Cancer Research UK ยท Tests: Atezolizumab Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer NCT06903858Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Toripalimab plus celecoxib, Non-operative management, Curative-intent surgery Research on Colorectal Cancer Recurrence Monitoring and Individualized Treatment Based on MRD NCT07775950NA1 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Discontinue NA Treatment, Continued Immunotherapy, Observation Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Metastatic Colorectal Cancer (CORESIM) NCT06353854n/a20 sites๐Ÿ“ Bayonne๐Ÿ“ Beauvais๐Ÿ“ Besanรงon Federation Francophone de Cancerologie Digestive Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer NCT05855200Phase 3266 sites๐Ÿ“ Tucson๐Ÿ“ Los Angeles๐Ÿ“ New Haven GlaxoSmithKline ยท Tests: Dostarlimab, CAPEOX, FOLFOX Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients NCT06098560n/a2 sites๐Ÿ“ Beijing๐Ÿ“ Shanghai Geneplus-Beijing Co. Ltd. Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer NCT06205836Phase 21 site๐Ÿ“ Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ยท Tests: Cemiplimab, Fianlimab PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer NCT05236972Phase 31 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Sintilimab, Oxaliplatin, capecitabine A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer NCT06686576Phase 31 site๐Ÿ“ Guangzhou Qilu Pharmaceutical Co., Ltd. ยท Tests: QL1706, CAPEOX/Capecitabine Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis NCT06047379Phase 1, Phase 28 sites๐Ÿ“ Beverly Hills๐Ÿ“ Glendale๐Ÿ“ Los Angeles Neonc Technologies, Inc. ยท Tests: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer NCT07076823Phase 11 site๐Ÿ“ Chengdu West China Hospital ยท Tests: Canagliflozin Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer NCT06520683Phase 31 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Tislelizumab, Adjuvant chemotherapy Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI Tumors NCT07829081n/a3 sites๐Ÿ“ Basel๐Ÿ“ Biel๐Ÿ“ Lucerne University Hospital, Basel, Switzerland ยท Tests: Active surveillance after complete response to immunotherapy in MMRd GI cancers, Stand of Care Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers NCT05239546Phase 22 sites๐Ÿ“ Iowa City๐Ÿ“ Madison University of Iowa ยท Tests: Dostarlimab The Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cancer With dMMR/MSI-H Guided by MRD Dynamic Monitoring: A Single-center, Open-label, Prospective, Phase II Clinical Trial. NCT06477991n/a1 site๐Ÿ“ Kunming Yunnan Cancer Hospital ยท Tests: Tireilizumab๏ผˆPD-1 inhibitor๏ผ‰ Botensilimab, Balstilimab, and SBRT in Colorectal Cancer NCT07128355EARLY Phase 11 site๐Ÿ“ Boston Massachusetts General Hospital ยท Tests: Stereotactic Body Radiation Therapy (SBRT), Botensilimab, Balstilimab Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer NCT06698757Phase 21 site๐Ÿ“ Zheng'zhou Yugui Lian ยท Tests: Sintilimab Patient Preference for Subcutaneous vs. Intravenous Immune Therapy NCT07223424Phase 21 site๐Ÿ“ Pittsburgh Diwakar Davar ยท Tests: nivolumab, pembrolizumab Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05) NCT07327489n/a8 sites๐Ÿ“ Fort Smith๐Ÿ“ Frederick๐Ÿ“ Springfield Elephas ยท Tests: Biopsy Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers NCT06580574Phase 21 site๐Ÿ“ Beijing Peking University ยท Tests: PD1/PDL1 antibody monotherapy, up to 24 weeks, Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks, Radicaโ€ฆ Safety and Efficacy of PD-1 ยฑ mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC NCT06002789Phase 21 site๐Ÿ“ Guangzhou Sixth Affiliated Hospital, Sun Yat-sen University ยท Tests: MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy, All-MSI-H (dMMโ€ฆ A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC NCT07244705Phase 1, Phase 215 sites๐Ÿ“ Liverpool๐Ÿ“ Macquarie Park๐Ÿ“ Randwick Anbogen Therapeutics, Inc. ยท Tests: ABT-301, Tislelizumab, Bevacizumab (Avastin) Phase โ…ก Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC NCT07003022Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: cadonilimab combined with an anti-angiogenic agent, which is selected by the investigator from bevacizumab, regorafenibโ€ฆ EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors NCT07262619Phase 1, Phase 245 sites๐Ÿ“ Los Angeles๐Ÿ“ Doral๐Ÿ“ Hialeah Eikon Therapeutics ยท Tests: EIK1005, pembrolizumab (KEYTRUDAยฎ ) A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivoยฎ, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer NCT06948448Phase 239 sites๐Ÿ“ Phoenix๐Ÿ“ Los Angeles๐Ÿ“ Lone Tree Ono Pharmaceutical Co., Ltd. ยท Tests: ONO-4578, Opdivoยฎ, Oxaliplatin, 5-Fluorouracil, Bevacizumab ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer NCT07841236Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: PD-1 inhibitor, CTLA-4 inhibitor, ctDNA/MRD testing, Curative Surgery Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer NCT07140679Phase 25 sites๐Ÿ“ Atlanta๐Ÿ“ Atlanta๐Ÿ“ Atlanta Emory University ยท Tests: Biopsy Procedure, Biospecimen Collection, Colonoscopy, Computed Tomography, Questionnaire Administration A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors NCT07213609Phase 1, Phase 227 sites๐Ÿ“ Aurora๐Ÿ“ Detroit๐Ÿ“ Canton GlaxoSmithKline ยท Tests: GSK5460025
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy